COMPOSITION FOR TREATING CANCER ASSOCIATED WITH HPV INFECTION

• US 20180044679A1
• Filed: 06/26/2017
• Published: 02/15/2018
• Est. Priority Date: 08/02/2012
• Status: Active Grant

• Current Assignee: EnhancedBio, Inc.
• Original Assignee: Abion Inc.
• Inventors: SHIN, Young Kee, KIM, Young Deug, JUNG, Hun Soon, KIM, Deuk Ae
• Granted Patent: US 10,221,418 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/02 for disorders of the vagina
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/1131 against viruses
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/122 Hairpin
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/322 2'-R Modification
• CPC Class Codes: C12N 2310/334 Modified C
• CPC Class Codes: C12N 2310/335 : Modified T or U
• CPC Class Codes: C12N 2310/336 : Modified G
• CPC Class Codes: C12N 2310/3521 : Methyl
• CPC Class Codes: C12N 2310/3533 : Halogen
• CPC Class Codes: C12N 2310/531 : Stem-loop; Hairpin

Abstract

The present invention relates to a composition for preventing or treating diseases associated with human papillomavirus (HPV), and more specifically, cancer associated with HPV, and even more specifically, cervical cancer. The nucleotide sequence of the present invention, the sequence in which the base thereof is modified, and a specific combination thereof can be useful in a composition for effectively treating diseases associated with HPV infection by greatly inhibiting the expression of the E6/E7 gene of HPV type 16 or 18.

Claims

1-26. -26. (canceled)

27. A method for preventing or treating a disease caused by HPV infection, the method comprising administering, to a subject, a pharmaceutical composition including:

(a) a pharmaceutically effective amount of nucleotide pool selected from the group consisting of;

a pool having nucleotide sequences of SEQ ID Nos;

2, 4, 8, 9, 12, and 15;

or a pool having nucleotide sequences of SEQ ID Nos;

58, 59, 63 and 65; and

(b) a pharmaceutically acceptable carrier.

28. The method of claim 27, wherein, the disease caused by HPV infection is selected from the group consisting of genital warts, vagina inflammation, pelvic inflammation and a cancer.

29. The method of claim 28, wherein, the cancer is selected from the group consisting of cervical cancer, vagina cancer, vulva cancer, anal cancer, penis cancer, tonsil cancer, pharynx cancer, larynx cancer, head and neck cancer and lung adenocarcinoma.

30. A method for treating or preventing a disease caused by HPV infection, the method comprising administering, to a subject, a pharmaceutical composition including:

(a) a pharmaceutically effective amount of one or more nucleotide pair selected from the group consisting of;

(i) a nucleotide pair of sequences comprising SEQ ID NOs;

2 and 4, respectively, (ii) a nucleotide pair of sequences comprising SEQ ID NOs;

8 and 9, respectively, (iii) a nucleotide pair of sequences comprising SEQ ID NOs;

12 and 15, respectively, (iv) a nucleotide pair of sequences comprising SEQ ID NOs;

13 and 14, respectively, (v) a nucleotide pair of sequences comprising SEQ ID NOs;

13 and 15, respectively, (vi) a nucleotide pair of sequences comprising SEQ ID NOs;

57 and 59, respectively, (vii) a nucleotide pair of sequences comprising SEQ ID NOs;

57 and 60, respectively, (viii) a nucleotide pair of sequences comprising SEQ ID NOs;

58 and 59, respectively, (ix) a nucleotide pair of sequences comprising SEQ ID NOs;

58 and 60, respectively, (x) a nucleotide pair of sequences comprising SEQ ID NOs;

58 and 61, respectively, and (xi) a nucleotide pair of sequences comprising SEQ ID NOs;

63 and 65; and

(b) a pharmaceutically acceptable carrier.

31. The method of claim 30, wherein, the nucleotide is siRNA.

32. The method of claim 30, wherein, the disease caused by HPV infection is selected from the group consisting of genital warts, vagina inflammation, pelvic inflammation and a cancer.

33. The method of claim 30, wherein, the cancer is selected from the group consisting of cervical cancer, vagina cancer, vulva cancer, anal cancer, penis cancer, tonsil cancer, pharynx cancer, larynx cancer, head and neck cancer, and lung adenocarcinoma.